Shuttle Pharmaceuticals is a clinical‐stage biopharmaceutical company focused on developing innovative therapies that address diseases of the central nervous system. Leveraging a proprietary shuttle‐mediated delivery platform, the company aims to enhance drug penetration across the blood‐brain barrier, providing targeted treatment options for neurological cancers and other CNS disorders. Shuttle Pharmaceuticals’ research pipeline includes multiple small-molecule candidates designed to improve therapeutic index and patient outcomes through optimized central nervous system exposure.
The company’s lead clinical program is centered on a novel kinase inhibitor for the treatment of glioblastoma multiforme, with ongoing Phase 1/2 trials assessing safety, tolerability and preliminary efficacy in adult patients. In parallel, Shuttle Pharmaceuticals has advanced a series of preclinical assets targeting metastatic brain tumors and neurodegenerative conditions. Collaborations with academic research centers in the United States and Europe support the company’s translational efforts, while proprietary chemistry and formulation capabilities underpin its differentiated approach to drug delivery.
Founded in 2017 and headquartered in Cambridge, Massachusetts, Shuttle Pharmaceuticals completed a Nasdaq initial public offering in 2022 to fund its expanding pipeline and clinical operations. The company maintains research sites in North America and a regulatory affairs office in Basel, Switzerland, enabling streamlined interactions with both the U.S. Food and Drug Administration and the European Medicines Agency. Strategic partnerships and license agreements have been established to accelerate development timelines and secure access to emerging therapeutic modalities.
Under the leadership of President and CEO Dr. Alexandra Reed, a veteran biopharma executive with extensive experience in CNS drug development, Shuttle Pharmaceuticals has built a management team with deep expertise in medicinal chemistry, translational biology and clinical program management. The company’s board of directors comprises industry experts and patient advocates committed to advancing science and improving outcomes for patients with neurological diseases.
AI Generated. May Contain Errors.
